Equities analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to post sales of $5.03 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Strongbridge Biopharma’s earnings, with estimates ranging from $3.10 million to $5.83 million. Strongbridge Biopharma posted sales of $2.98 million in the same quarter last year, which suggests a positive year-over-year growth rate of 68.8%. The company is scheduled to report its next quarterly earnings report on Monday, March 11th.

On average, analysts expect that Strongbridge Biopharma will report full-year sales of $18.53 million for the current financial year, with estimates ranging from $16.61 million to $19.30 million. For the next financial year, analysts expect that the business will post sales of $28.69 million, with estimates ranging from $24.88 million to $30.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.06). The business had revenue of $5.35 million during the quarter, compared to the consensus estimate of $5.48 million.

A number of analysts have weighed in on the company. Zacks Investment Research cut Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. ValuEngine cut Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, November 12th. Cantor Fitzgerald set a $17.00 price objective on Strongbridge Biopharma and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Finally, Laidlaw assumed coverage on Strongbridge Biopharma in a research report on Tuesday, December 18th. They set a “buy” rating and a $11.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $14.13.

In other Strongbridge Biopharma news, major shareholder Associates L.L.C. Cdk bought 49,397 shares of the business’s stock in a transaction dated Thursday, December 27th. The stock was acquired at an average cost of $3.99 per share, with a total value of $197,094.03. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.20% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of Strongbridge Biopharma during the 2nd quarter worth approximately $110,000. GSA Capital Partners LLP purchased a new position in Strongbridge Biopharma in the 2nd quarter valued at approximately $204,000. Paloma Partners Management Co purchased a new position in Strongbridge Biopharma in the 2nd quarter valued at approximately $817,000. California Public Employees Retirement System purchased a new position in Strongbridge Biopharma in the 2nd quarter valued at approximately $185,000. Finally, Alps Advisors Inc. increased its stake in Strongbridge Biopharma by 25.1% in the 3rd quarter. Alps Advisors Inc. now owns 82,657 shares of the biotechnology company’s stock valued at $401,000 after purchasing an additional 16,574 shares in the last quarter. 65.68% of the stock is owned by institutional investors and hedge funds.

Strongbridge Biopharma stock traded up $0.27 during mid-day trading on Friday, reaching $4.99. 123,300 shares of the company were exchanged, compared to its average volume of 117,888. Strongbridge Biopharma has a twelve month low of $3.82 and a twelve month high of $9.25. The company has a current ratio of 3.38, a quick ratio of 3.11 and a debt-to-equity ratio of 8.76. The stock has a market capitalization of $222.81 million, a price-to-earnings ratio of -3.44 and a beta of 0.09.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Recommended Story: How do candlesticks reflect price movement?

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.